Functional p53 in cells contributes to t
✍
Martina Paprskářová; Vladimír Kryštof; Radek Jorda; Petr Džubák; Marián Hajdúch;
📂
Article
📅
2009
🏛
John Wiley and Sons
🌐
English
⚖ 382 KB
## Abstract Inhibitors of cyclin‐dependent kinases (CDKs) undergoing clinical trials as anticancer agents usually target several CDKs in cells. Some of them are also able to increase cellular levels of p53 protein and to activate p53‐regulated transcription. To define the role of p53 in the antican